| Date | Title | Description | |
|---|---|---|---|
| 17 May 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 10 May and 16 May 2024 | Download |
| 10 May 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 2 May and 9 May 2024 | Download |
| 08 May 2024 | Announcement of General Shareholders’ Meeting | The Company announces the decision of its Board of Directors to convene the Ordinary General Shareholders' Meeting | Download |
| 30 Apr 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 26 April and 30 April 2024 | Download |
| 26 Apr 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 19 April and 25 April 2024 | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 08 Oct 2018 | Share capital increases and reductions | Information on the registration in the Commercial Registry of Madrid of the notarial deed regarding the capital increase | Download |
| 05 Oct 2018 | Buy-back programmes, stabilisation and treasury stock | Information about the possibility that Jefferies International Limited carries out stabilisation transactions within the framework of the capital increase excluding pre-emptive subscription rights of the existing shareholders of Laboratorios Farmacéuticos Rovi, S.A. | Download |
| 04 Oct 2018 | Share capital increases and reductions | Directors’ Report and Independent Expert Report related to capital increase excluding preferential subscription rights | Download |
| 04 Oct 2018 | Liquidity contracts and specialists | The Company informs that has temporarily suspended liquidity agreement with JB Capital Markets, Sociedad de Valores, S.A.U. | Download |
| 04 Oct 2018 | Share capital increases and reductions | Information on price fixing and outcome of the private placement related to capital increase addressed to institutional investors, excluding preferential subscription rights | Download |